drugset / Trial / NCT00117065

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

NCT00117065 ↗

Phase 4 Completed Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic — Subcutaneous

Indications